item management s discussion and analysis of financial condition and results of operations overview the following discussion should be read in conjunction with the financial statements and related notes appearing elsewhere herein 
the company develops  manufactures  markets and sells orthopaedic implant devices  related surgical instrumentation  and distributes biologic materials to hospitals and physicians in the united states and overseas 
early in its history  the company s revenues were principally derived from sales of its primary hip replacement systems 
currently  however  the company s revenues are principally derived from sales of its knee and hip replacement systems 
during  of the company s revenues were derived from sales of knee replacement systems while of the company s revenues were derived from sales of hip replacement systems 
in addition  the company derives revenues from worldwide distribution of bone paste products processed for use in non spinal musculoskeletal orthopaedic procedures 
during  of the company s revenues were derived from distribution of bone paste products 
in  the company began distributing a unique bone cement system  cemex  under an exclusive agreement with italian manufacturer  tecres spa the cemex bone cement system features a self contained delivery system that has been clinically proven in europe for more than a decade 
by integrating bone cement powder and liquid into a sealed mixing system  cemex is designed to offer surgeons and operating room personnel simplicity  safety and reliability in bone cement 
in march  the company entered into a distribution agreement with link  a german manufacturer of joint replacement systems  to distribute link s orthopaedics products in the united states 
link implants are complimentary to the company s total joint systems by addressing clinical indications outside the scope of the company s product design 
late in  the company acquired all of the inventory and intellectual property of teknimed  a french manufacturer that related to teknimed s patented total shoulder system 
to market orthopaedic implant products in the united states  exactech utilizes a network of independent agencies and domestic distributors that act as the company s sales representatives 
internationally  the company s products are marketed through distributors 
the following two tables include i the net revenue and percentage of net sales for each of the company s product lines for the years ended december   and and ii items from the statements of income for the years ended december    and  the percentage relationship to net sales and the percentage change from year to year sales revenue by product line dollars in thousands year ended december  december  december  knee implants hip implants tissue services other products total 
table of contents percentage of net sales percentage change statement of income data vs 
vs 
net sales cost of goods sold gross profit sales and marketing expenses general and administrative expenses research and development expenses depreciation and amortization royalties total operating expenses income from operations other income expenses  net income before provision for income taxes provision for income taxes net income year ended december  compared to year ended december  net sales increased by to  in from  in worldwide sales of knee implant systems increased by to  in from  in the systems contributing to this growth include the optetrak comprehensive knee system and the link endo model rotational knee 
worldwide sales of hip implant systems increased to  in from  in the hip systems contributing to this increase include the acumatch integrated hip system as well as the link hip products 
worldwide service revenue from distribution of opteform tissue increased to  in from  in sales and rental of surgical instrumentation  including the acudriver automated osteotome system  increased to  in from  in sales of other products increased to  in from  in sales of other products include distribution of bone cement  various instruments and supplies under the link distribution agreement  a limited distribution of bone plates and screws for trauma procedures and limited distribution of the link star ankle system 
domestic sales revenue increased to  in from  in this increase was driven by the expansion of the company s distribution network  in part related to the distribution agreements with link and rti 
international sales revenue increased to  in  representing of net sales revenue  from  in  representing of net sales revenue  primarily as a result of strong growth in southern europe and expanded distribution overseas through the addition of three international distributors 
gross profit increased to  in from  in the gross profit margin increased to in from in the growth in gross profit margin is attributable to improved manufacturing efficiencies achieved through internal manufacturing processes and realization of one time net revenue of approximately  on licensed tissue services distributed by rti as part of the arbitration settlement agreement 
included in gross profit is a loss on disposal of assets  which increased to  in from  in as a result of the retirement of older surgical instrumentation 
the company expects that gross profit margins in will be between the and levels 
sales and marketing expenses increased to  in from  in this increase is primarily attributable to increases in variable selling costs associated with sales growth  such as commissions paid to the company s independent agents for servicing surgeon and hospital accounts 
as a percentage of sales  sales and marketing expenses were in as compared to in factors contributing to this increase were marketing initiatives in the area of targeted market development campaigns  distribution network expansion efforts and the assumption of distribution of the link orthopaedics products in march the company expects that sales and marketing expenses will remain constant as a percentage of sales in as the company continues to invest in expansion of the sales and marketing network as well as target marketing programs 

table of contents general and administrative expenses increased to  in from  in the increase was primarily a result of increases in product liability insurance premiums and costs associated with distribution of link s orthopaedics products 
as a percentage of sales  general and administrative expenses were in as compared to in general and administrative expenses remained relatively constant  as a percentage of sales  because the reduction in legal expenses in as a result of the arbitration settlement with rti was offset by the increases in product liability insurance 
the company expects a small reduction in general and administrative expenses as a percentage of sales in  although the achievement of that reduction will be largely dependent on the cost of product liability insurance premium renewals and legal expenses which traditionally have been difficult to estimate 
research and development expenses increased to  in from  in as a percentage of sales  research and development expenses remained constant at in and the dollar increase in research and development expenses was a result of the company s continuing efforts in developing new product technologies  product line extensions and clinical outcomes research  while maintaining development funding at a level supported by top line sales growth 
the company expects an increase in research and development expenses of up to a of sales in to support the hip and knee new product pipeline and the continued development of the shoulder and diamond bearing technology 
depreciation and amortization expenses increased to  in as compared to  in the increase was primarily the result of continued capital investment in surgical instrumentation in support of product line extensions and expansion of the company s distribution network 
in  the company invested  in surgical instrumentation 
as a percentage of sales  depreciation and amortization expenses were in and in the company expects depreciation and amortization expenses to continue around the level as a percentage of sales as a result of continued investment in surgical instrumentation and the expansion of the company s principal facility 
royalty expenses increased to  in from  in the increase was driven by strong growth in sales of knee and hip implant products 
as a percentage of sales  royalty expenses were in as compared to in this decrease  as a percentage of sales  was the result of the expiration of certain royalty agreements on the knee implant products 
income from operations increased to  in from  in the increase was primarily the result of the strong sales growth  as well as production cost improvements 
as a percentage of sales  income from operations was in as compared to in other income net of other expenses resulted in other income of  in as compared to other expense of  in included in other income and expenses is interest expense  which decreased to  in from  in due to the repayment of borrowings under the company s line of credit  loss of foreign currency of  in as a result of euro denominated inventory purchases  and equity in the loss of the company s asian joint venture of  in as compared to  in other expenses were offset by interest income of  in as compared to  in and litigation settlement payments received in of  net of legal costs of  in connection with the arbitration settlement agreement with rti 
the company expects other income and expenses to result in net other income of  to  in as the remaining rti settlement payments of  will be offset by increases in interest expense and equity in joint venture 
income before provision for income taxes increased to  in from  in the provision for income taxes increased to  or of income before taxes  in  from  or of income before taxes  in as a result of strong domestic sales growth  as a percentage of total sales  and reduction in the tax benefit of international sales 
the company expects for income taxes to be in a range of to in as a result of the foregoing  the company realized net income of  in  an increase of  from  in net income represented of sales as compared to in diluted earnings per share increased to 
in from 
in 
table of contents year ended december  compared to year ended december  during  the company s results of operations were significantly impacted by costs associated with an arbitration dispute with rti 
overall trends in sales growth of mechanical joint replacement systems were positive in when compared to net sales increased to  in from  in worldwide sales of the optetrak comprehensive knee system increased to  in from  in sales of hip implant systems increased worldwide to  in from  in the introduction of the first components in the company s comprehensive acumatch integrated hip system  including the a series acetabular components and the m series modular hip stem system contributed to this growth 
revenue from worldwide distribution of tissue services decreased to  in from  in the uncertainty of the outcome of the arbitration dispute with rti was a contributing factor in this reduction 
net sales of surgical instrumentation and other products increased to  in from  in products contributing to this growth were the company s surgical instrumentation sold to international distributors and the cemex bone cement system 
domestic sales increased to  in from  in the increase was primarily due to the introduction of improved hip implant products and continued market penetration and acceptance of the company s knee systems 
international sales increased to  in  representing of net sales  from  in  which was also of net sales 
the entry into new markets in europe  south america and australia fueled this growth in foreign sales 
gross profit increased to  in from  in the increase in gross profit was consistent with total increases in net sales 
gross profit margin remained constant at in and included in gross profit was a loss on disposal of assets  which increased to  in from  in loss on disposal of assets for and was reclassified from other income and expenses to cost of sales to be consistent with the presentation 
sales and marketing expenses increased to  in from  in the increase was the result of marketing initiatives in the areas of training and meetings 
in  the company hosted its first worldwide surgeons conference that was attended by hundreds of surgeons from the united states and overseas 
as a percentage of sales  sales and marketing expenses increased to in from in as a result of the increased expenditures associated with supporting the training and meeting initiatives 
general and administrative expenses increased to  in from  in the increase was primarily the result of  of legal costs associated with arbitration and litigation issues 
as a percentage of sales  general and administrative expenses were in as compared to in research and development expenses increased to  in from  in as a percentage of total sales  research and development expenses were in as compared to in this decrease in development costs  as a percentage of sales  was primarily due to the completion in of significant development efforts associated with the company s comprehensive improvement and line extension projects on its integrated hip system 
depreciation and amortization expenses increased to  in from  in the increase was principally due to the investment in surgical instrumentation and manufacturing equipment 
in  the company invested  in instruments and manufacturing equipment 
as a percentage of sales  depreciation and amortization expenses were in as compared to in royalty expenses increased to  in from  in this increase was consistent with the overall increase in sales of hip and knee implants  the product lines incurring royalties 
as a percentage of sales  royalty expenses decreased slightly to in from in as a result of a change in the sales mix between knee and hip implant products 
income from operations decreased to  in from  in the decrease resulted from the increases in the operating expenses outpacing the top line sales growth 
as a percentage of sales  income from operations was in as compared to in  reflecting the increase in operating 
table of contents expenses while gross profit margin remained constant 
other expenses  net increased to  in from  in included in other income and expenses is interest expense  which increased to  in from  in as a result of borrowing under the company s line of credit  interest income which decreased to  from  in and the company s equity in the net loss of its asian joint venture of  in  its first year of operations 
income before provision for income taxes decreased to  in from  in the provision for income taxes decreased to  or of income before taxes  in from  or of income before taxes  in the decrease in the effective tax rate was primarily the result of the impact of the research and development credit and the tax benefits from foreign sales 
as a result of the foregoing  the company realized a decrease in net income of to  in from  in earnings per share  on a diluted basis  decreased to 
in compared to 
in liquidity and capital resources the company s cash and cash equivalents increased to  at december  from  at december  and  at december  at december   the company had working capital of  as compared to  at december  and  at december  during  the increase in working capital was primarily the result of the  increase in cash balances and the  increase in trade receivables 
during  the increase in working capital was the result of the  increase in cash balances and the  increase in trade receivables 
trade receivables are expected to increase commensurate with sales growth in the short and long term as the company is not anticipating any significant changes in its credit terms 
the company had significant cash flows from operations for each of the last two years due to the increases in sales and profitability while improving receivables and inventory management 
the company expects to be cash flow neutral for the short term as it is expecting that positive cash flows due to profitability will be used for additional investment in inventory  surgical instrumentation  and continued technology and product line asset purchases 
the company maintains a credit facility with merrill lynch business financial services  inc  which is secured by accounts receivable and inventory credit line 
the credit line is limited to the lesser of of the value of accounts receivable less than days old  plus the lesser of of the value of inventory excluding raw materials and work in process inventory and of inventory on consignment or  the credit line was renewed in june maintaining the available limit at  expiring june  as of december   there were no amounts outstanding under the line of credit as compared to  at december  the company continues to maintain an industrial revenue bond financing secured by a letter of credit with a local lending institution that was funded in for construction of the company s current facility 
the balance due under the bond as of december  was  as of december  the company was in the process of a significant expansion to the corporate facility and entered into a long term commercial construction loan of up to  with a local lending institution to fund the expansion 
at december   there was  outstanding under this loan 
during february  the company entered into but has not drawn upon an additional long term loan of up to  with a local lending institution for purposes of acquiring office and manufacturing equipment 
at december   the company had outstanding commitments for the purchase of inventory and raw materials of  along with commitments to purchase  of capital equipment 
the company believes that funds from operations and borrowings under its existing credit facilities will be sufficient to satisfy its contemplated cash requirements for the following twelve months 
operating activities operating activities provided net cash of  in  as compared to  in  while using net cash of  in during and  operating activities provided net cash primarily as a result of the increase in sales and net income without proportionate increases in receivables and inventory 
during  operating activities used net cash primarily as a result of an increase in inventory of  made in support of new product development 
during  cash used as a result of the increase in trade receivables was  as compared to  during and  during cash used as a result of an increase in inventory during was  as compared to  in the company s focus on inventory management efforts during and resulted in inventory increases far lower than the increase in sales 
inventory levels are expected to increase in the short term due to the expected increase in 
table of contents sales although average inventory turns of 
are expected to remain constant 
during cash provided as a result of an increase in accounts payable was  compared to cash used as a result of a decrease in accounts payable of  in investing activities during  net cash used in investing activities increased to  as compared to  used during  and  used during the increase during was the result of continued rollout of new product lines and related surgical instrumentation as well as the construction in progress related to the facilities expansion 
in  total capital expenditures are expected to be between  to  due to significant increases in surgical instrumentation and the completion and buildout of the facility expansion that is expected to be approximately  of the total 
financing activities during  financing activities provided net cash of  as compared to using net cash of  in and providing net cash of  in during  the company used cash of  to pay outstanding long and short term debt as compared to  used for similar purposes in proceeds from issuance of stock related to option and warrant exercises decreased to  in from  in borrowings under credit lines and other loans provided cash of  in   in and  in during  the company anticipates to fully draw down both the  associated with the facility expansion loan and the  associated with the expansion equipment loan 
the company does not foresee having to execute any borrowings under the credit line unless there are significant asset and or technology purchase opportunities 
contractual obligations and commercial commitments the following table indicates the company s contractual obligations at december  in thousands payments due by period contractual obligations total thereafter industrial revenue bond commercial construction loan facility lease purchase obligations at december   the company did not have any off balance sheet financing arrangements other than operating leases as discussed in note of the notes to financial statements or any unconsolidated  special purpose entities 
critical accounting policies and estimates management s discussion and analysis of its financial position and results of operations are based on the company s financial statements  which have been prepared in accordance with accounting principles generally accepted in the united states of america 
the preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets  liabilities  revenues and expenses and related disclosure of contingent assets and liabilities 
the company s significant accounting policies are discussed in note of notes to financial statements 
in management s opinion  the company s critical accounting policies include allowance for doubtful accounts  excess and obsolete inventories  intangible assets  and accrued liabilities 
allowance for doubtful accounts the company maintains an allowance for doubtful accounts to estimate the losses due to the inability to collect required payment from our customers for products and services rendered 
should the financial condition of our customers deteriorate  resulting in an impairment of their ability to pay  additional allowances may be required which would affect the company s future operating results 
excess and obsolete inventories in the orthopeadic device industry  significant amounts of consigned inventory are typically utilized to meet the product needs of medical care providers 
since human anatomy differs  a wide variety of size options is necessary to meet the varying needs of patients undergoing musculoskeletal procedures 
although larger and smaller sizes may be infrequently used  inventories of all sizes must be available to meet the widest array of patient needs 
in addition to large inventory requirements  the orthopaedic device industry 
table of contents is highly competitive with new products  raw materials and technologies being introduced continually  which may obsolete existing product inventories 
the company makes estimates concerning the future use of these products and calculates a provision for excess and obsolete inventories 
if the actual product life cycles  demand or general market conditions are less favorable than those projected by management  additional inventory write downs may be required which would affect future operating results 
intangible assets in assessing the value of the company s intangible assets  the company must make assumptions regarding the estimated future cash flows  economic life and other factors to determine fair value of the respective assets 
if these estimates or assumptions change in the future  the company may be required to record an impairment charge for these assets 
the company adopted statement of financial accounting standards no 
goodwill and other intangible assets on january   has analyzed its intangible assets for impairment issues  and will continue to do so on an annual basis 
accrued liabilities as a result of product liability and other claims  the company establishes accruals for losses that are deemed to be probable and subject to reasonable estimate 
there are various claims  lawsuits  and disputes with third parties  as well as pending actions involving various allegations against the company incident to the operation of its business  principally product liability cases 
should the outcome of any pending  threatened  or future litigation have an outcome unfavorable to the company  it may affect future operating results 
certain risk factors although it is not possible to predict or identify all such factors  they may include those listed below  which should not be considered an exhaustive statement of all potential risks and uncertainties the company is subject to extensive government regulation 
failure to obtain government approvals and clearances for new products and or modifications to existing products on a timely basis would likely have a material adverse effect on the business and financial results of the company 
a significant recall of one or more of the company s products could have a material adverse effect on the company s business and financial results 
there can be no assurance that such clearances will be granted or that review by government authority will not involve delays materially adversely affecting the marketing and sale of the company s products 
the company faces uncertainty relating to the availability of third party reimbursement for its products 
the failure by physicians  hospitals and other users of the company s products to obtain sufficient reimbursement from health care payors for procedures in which the company s products are used or adverse changes in governmental and private payors policies toward reimbursement for such procedures would have a material adverse effect on the company s business and financial results 
the company is required to incur significant expenditures of resources in order to maintain relatively high levels of inventory 
as a result of the need to maintain substantial levels of inventory  the company is subject to the risk of inventory obsolescence 
in the event that a substantial portion of the company s inventory becomes obsolete  it would have a material adverse effect on the company s business and financial results 
the company conducts business in a highly competitive industry 
the orthopaedic implant industry is subject to competition in the following areas product features and design  innovation  service  the ability to maintain new product flow  relationships with key orthopaedic surgeons and hospitals  strength of distribution network  and price 
in addition  the company faces competition for regional sales representatives within the medical community 
there can be no assurance that the company will be able to compete successfully 
the company s success is partially dependent upon its ability to successfully market new and improved products and the market acceptance of those products 
the failure of its products to gain market acceptance would be likely to have a material adverse effect on the company s business and financial results 
there can be no assurance that new or improved products will gain market acceptance 
the company is subject to federal anti kickback laws and regulations 
these laws and regulations prohibit any knowing and willful offer  payment  solicitation or receipt of any form of remuneration  either directly or indirectly  in return for  or to induce referral of an individual for a service or product for which payment may be made by medicare  medicaid or another government sponsored health care program  or purchasing  leasing  ordering or arranging for  or recommending the purchase  lease or order of  any service or product for which payment may be made by a government sponsored health care program 
there can be no assurance that federal or state regulatory authorities will not challenge the company s current or future activities under these laws 
any challenge by those regulatory authorities could have a 
table of contents material adverse effect on the company s business or financial results 
any state or federal regulatory review of the company  regardless of the outcome  would be costly and time consuming 
the company holds patents on specific designs and processes and relies on trade secrets and proprietary know how which can provide it with a competitive advantage 
the company also employs various methods to protect its proprietary information  including confidentiality agreements and proprietary information agreements 
there can be no assurance as to the breadth or degree of protection which existing or future patents  if any  may afford the company  that those confidential or proprietary information agreements will not be breached  that the parties from whom the company has licensed or otherwise acquired patent rights  proprietary rights and technology have full rights to those patent rights and technology  or that the company s trade secrets and proprietary know how will not otherwise become known to or independently developed by competitors 
the company must devote substantial resources to research and development 
there can be no assurance that the company will be successful in developing competitive new products and or improving existing products so that its products remain competitive and avoid obsolescence 
the company is subject to potential product liability risks which are inherent in the design  marketing and sale of orthopaedic implants and surgical instrumentation 
no assurance can be given that the company will not face claims resulting in substantial liability for which the company is not fully insured or that the company will be able to maintain adequate levels of insurance on acceptable terms 
a partially or completely uninsured successful claim against the company of sufficient magnitude could have a material adverse effect on the company s business and financial results 
recent accounting pronouncements see note of notes to the financial statements for information concerning recent accounting pronouncements 
item a 
quantitative and qualitative disclosures about market risk the company is exposed to market risk from interest rates 
for its cash and cash equivalents  a change in interest rates effects the amount of interest income that can be earned 
for its debt instruments  changes in interest rates effect the amount of interest expense incurred 
the following table provides information about the company s financial instruments that are sensitive to changes in interest rates 
the amounts presented approximate the financial instruments fair market value as of december  in thousands  except percentages thereafter total cash and cash equivalents overnight repurchase account at variable interest rate weighted average interest rate liabilities industrial revenue bond at variable interest rate weighted average interest rate commercial construction loan at variable interest rate weighted average interest rate the company invoices and receives payment from international distributors in u 
s 
dollars and is not subject to risk associated with foreign currency exchange rates on accounts receivable 
in connection with certain distribution agreements  the company is subject to risk associated with foreign currency exchange rates on purchases of inventory payable in euros 
the company does not invest in foreign currency derivatives 
the us dollar is considered the primary currency for the company and transactions that are completed in a foreign currency are translated into us dollars and recorded in the financial statements 
translation gains or losses were not material in any of the periods presented and the company does not believe it is currently exposed to any material risk of loss on this basis 

table of contents 
